15Jan
20Dec
Corbus Readies Pivotal Phase 3 Trial of Anabasum, Possible Scleroderma Treatment
Corbus Pharmaceuticals is planning a global Phase 3 trial to assess anabasum (JBT-101) as a treatment for scleroderma. If successful, the company plans to apply to regulatory authorities, asking that anabasum be the first specifically approved treatment for scleroderma. Read more >>
15Dec
Boston Harbor Angels Awards Portfolio Companies at Annual Meeting
Boston Harbor Angels, one of the top three elite angels groups in the US, recognized three portfolio companies at its annual end-of-year general meeting. Exit of the Year Award: Corbus Pharmaceuticals on NASDAQ Biotech Startup of the Year Award: Astrocytes Pharmaceuticals Inc. IT Startup of the Year Award: Wasabi The meeting featured interviews with Yuval Cohen, CEO of Corbus Pharmaceuticals and Mark Tepper, President & Chief Scientific Officer of Corbus Pharmaceuticals; and David Friend, CEO and co-founder of Wasabi. The group also honored Mic Williams,...
28Nov
Corbus Pharmaceuticals Expands Intellectual Property Portfolio with Patent Issuance Covering the Use of Anabasum for the Treatment of Rare Fibrotic Diseases
Corbus Pharmaceuticals Holdings, Inc., a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that the U.S. Patent and Trademark Office ("USPTO") issued U.S. Patent No. 9,820,964 to the Company with claims covering the use of pharmaceutical compositions comprising anabasum for the treatment of multiple fibrotic diseases, including the Company's lead indications: systemic sclerosis, dermatomyositis, cystic fibrosis as well as others. Read more >>
10Nov
75% of Scleroderma Patients Show Meaningful Skin Improvement with Anabasum, Extension Study Shows
The thick skin that is a hallmark of scleroderma showed meaningful improvement in 75 percent of patients treated with Corbus Pharmaceuticals’ anabasum (JBT-101), according to initial results of an extension trial. Read more >>
04Nov
Corbus Pharmaceuticals Receives Anabasum Patent for Inflammatory, Fibrotic Diseases
Corbus Pharmaceuticals recently announced that the U.S. Patent and Trademark Office has issued a patent for the use of anabasum, the company’s lead therapy candidate for the treatment of inflammatory and fibrotic diseases. Read more >>
26Oct
Corbus Pharma (CRBP) Announces Proposed Public Common Offering
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) today announced that it plans to offer shares of its common stock in an underwritten public offering. Read more >>
21Sep
Corbus Pharmaceuticals Announces Presentation of Six Abstracts and New Anabasum Data at 2017 ACR Annual Meeting
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that its abstracts have been selected for presentations at the American College of Rheumatology ("ACR") 2017 Annual Meeting being held November 3-8, 2017 in San Diego, California. Read more >>
15Sep
Corbus Pharmaceuticals to Present at the Cantor Fitzgerald Global Healthcare Conference
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) ("Corbus" or the "Company"), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, announced today that Yuval Cohen, Ph.D., Chief Executive Officer, will present at the Cantor Fitzgerald Global Healthcare Conference on Monday, September 25, 2017 at 8:35 a.m. EDT in New York, NY. Read more >>
02Sep